This thread covers the pharmacology of GH peptides in more depth than the Overview piece. Two receptor systems, two mechanisms, two half-life patterns — and synergy when both are activated together. Understanding this is the key to understanding why research protocols in this category look the way they do.
The two receptors.
The GHRH receptor. Located on pituitary somatotrophs (the cells that produce growth hormone). When activated, it triggers cAMP-mediated GH release. The endogenous ligand is growth hormone-releasing hormone, a 44-amino-acid peptide released from the hypothalamus in pulses primarily during deep sleep.
The GHSR-1a receptor (Growth Hormone Secretagogue Receptor type 1a). Located on pituitary somatotrophs and elsewhere in the brain (hypothalamus, hippocampus). When activated, it triggers GH release through a different signaling cascade involving phospholipase C and IP3-mediated calcium release. The endogenous ligand is ghrelin, a 28-amino-acid peptide released primarily from the stomach.
Why the pathways are synergistic.
Activating both receptors simultaneously produces more GH release than either alone — significantly more, not just additive. The GHRH pathway primes the somatotrophs and the ghrelin pathway amplifies the release. This is the pharmacological basis for the CJC-1295 + ipamorelin combination that has dominated the research literature for over a decade. A GHRH analog alone produces moderate GH release; a ghrelin mimetic alone produces moderate GH release; the combination produces a release pulse that approaches what the natural sleep-onset GH pulse looks like in a young healthy subject.
Half-life landscape — GHRH analogs.
Half-life landscape — Ghrelin mimetics.
Pulsatility — why it matters.
Endogenous GH is not released continuously. It comes out in discrete pulses, primarily during deep sleep, with smaller pulses during the day in response to exercise, fasting, and other stimuli. The pulsatile pattern is biologically important — sustained GH elevation produces different downstream effects than pulsatile elevation, and the pulsatile pattern appears to be what the IGF-1 axis and tissue receptors are evolutionarily adapted to.
This is why research protocols designed to mimic natural physiology favor short-acting compounds dosed multiple times per day rather than long-acting compounds providing continuous elevation. Mod GRF 1-29 + ipamorelin dosed three times per day produces a pulsatile pattern. CJC-1295-with-DAC produces a sustained elevation that is pharmacologically different — useful for some research questions but not the same as restoring natural pulsatility.
The MK-677 case is particularly interesting from a research design standpoint. Because it has a 24-hour half-life and oral bioavailability, it produces sustained GH/IGF-1 elevation throughout the day rather than discrete pulses. This produces different physiological responses than pulsatile secretagogues — including the well-documented water retention and increased hunger that are absent or much reduced with pulsatile injectables. Whether this sustained-elevation approach is "better" or "worse" depends entirely on what the research question is.
Tachyphylaxis and receptor desensitization.
Both pathways exhibit some degree of receptor desensitization with continuous exposure. The pituitary somatotrophs reduce responsiveness when continuously stimulated. This is one reason research protocols typically include cycling — periods on and periods off — and why short-acting pulsatile compounds may produce better long-term outcomes than continuous-elevation compounds at equivalent total exposure. The cycling thread in the Stacks & Protocols category covers this in more depth.
Why timing relative to food matters.
Both ghrelin mimetics and GHRH analogs work better when administered in a fasted or low-insulin state. Insulin suppresses GH release. Eating immediately before injecting blunts the GH pulse. This is the pharmacological reason research protocols typically involve dosing before bed (overnight fasting) and 30-60 minutes before or after meals during the day.
Practical takeaway.
The mechanism and half-life information directly drives protocol design. Pulsatile mimicking of natural physiology favors short-acting compounds dosed 2-3 times daily. Sustained elevation is a different research question entirely and uses long-acting compounds dosed less frequently. Combination of GHRH + ghrelin pathways produces stronger pulses than either alone. Insulin and recent food blunt the pulse — fasted dosing is the standard.
The deeper threads in this category cover specific applications — the CJC with-DAC versus without-DAC thread, the ipamorelin selectivity thread, the MK-677 oral comparison, the blood work timing thread, and the tesamorelin versus CJC comparison.
